<?xml version="1.0" encoding="utf-8"?>
 <journal>
 <language></language>
 <journal_id_issn></journal_id_issn>
 <journal_id_issn_online></journal_id_issn_online>
 <journal_id_pubmed></journal_id_pubmed>
 <journal_id_pii></journal_id_pii>
 <journal_id_doi></journal_id_doi>
 <journal_id_isnet></journal_id_isnet>
 <journal_id_iranmedex></journal_id_iranmedex>
 <journal_id_magiran></journal_id_magiran>
 <journal_id_sid></journal_id_sid>

 <pubdate>
	<type>jalali</type>
	<year>1389</year>
	<month>4</month>
	<day>1</day>
 </pubdate>
 <pubdate>
	<type>gregorian</type>
	<year>2010</year>
	<month>6</month>
	<day>22</day>
 </pubdate>
 <volume>4</volume>
 <number>2</number>

 <publish_type>online</publish_type>
 <publish_edition>1</publish_edition>
 <article_type>fulltext</article_type>

<articleset>
	<article>
	<language></language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed></article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_isnet></article_id_isnet>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	
	<title_fa></title_fa>
	<title>Maintenance Therapy by Vaginal Progesterone after Threatened Idiopathic Preterm Labor: A Randomized Placebo-Controlled Double-blind Trial</title>
	<subject_fa/>
	<subject/>
	
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	
	
	<abstract_fa></abstract_fa>
	<abstract>Background: Patients with arrested preterm labor (PTL) are at increased risk for recurrence of
preterm birth (PTB). Maintenance tocolysis after arrest of acute PTL is of questionable value. The
objective of this study was to evaluate the efficacy of 200 mg vaginal progesterone in order to
prevent PTB in women with episodes of threatened PTL.
Materials and Methods: This is a randomized double blind clinical trial study.Women with singleton
pregnancies between 28-36 weeks of gestation, who were hospitalized for PTL were included. A
total of 173 pregnant patients were randomly allocated to receive 200 mg vaginal progesterone
suppositories (n=86) or placebo (n=87) daily until the 36th gestational week. The two groups were
compared relative to demographic characteristics, incidence of PTB before 34 and 37 weeks, and
maternal and neonatal complications. Data were analyzed by chi-square and Fisher’s exact tests.
Results: Mean latency until delivery in the cases was longer than the control group (23.88 ± 18.01
vs. 16.67 ± 12.9; p=0.004).Treatment with progesterone was not associated with a reduction in
the rate of PTB before 34 weeks [cases: 9 (10.8%) vs. controls: 8 (10%)] and 37 weeks [cases: 45
(54.2%) vs. controls: 33 (41.2%)]. Log rank analysis revealed a significant difference for mean time
to delivery between the two groups (p=0.028). There were no significant differences for neonatal
and maternal complications in the two groups.
Conclusion: Prophylactic administration of 200 mg vaginal progesterone suppositories after
successful tocolysis in patients with threatened idiopathic PTL is associated with a longer latency
to delivery, but failed to reduce the rate of PTB (Registeration Number: IRCT138706051096N1).</abstract>

	<keyword_fa></keyword_fa>
	<keyword>Preterm Labor, Preterm Birth, Vaginal Tablet, Progesterone</keyword>
	<start_page>45</start_page>
	<end_page>50</end_page>
	<web_url></web_url>
	<web_url></web_url>
	<author_list>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Seyede Hajar Sharami, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email>sharami@gums.ac.ir</email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Ziba Zahiri, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Maryam Shakiba, M.Sc</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Frozan Milani, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	</author_list>
</article>
  <article>
	<language></language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed></article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_isnet></article_id_isnet>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	
	<title_fa></title_fa>
	<title>The Effect of Luteal Phase Support on Pregnancy Rates of the Stimulated Intrauterine Insemination Cycles in Couples with Unexplained Infertility</title>
	<subject_fa/>
	<subject/>
	
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	
	
	<abstract_fa></abstract_fa>
	<abstract>Background: To assess the efficacy of luteal phase support (LPS) with vaginal progesterone
(P) on pregnancy rates of the stimulated intrauterine insemination (IUI) cycles in couples with
unexplained infertility (UEI).
Materials and Methods: This was a single-center, prospective, randomized, blinded control trial
undertaken at a tertiary care university fertility center between October 2007 and December 2008.
A total of 200 couples with UEI underwent 511 consecutive stimulated IUI cycles.
Clomiphene citrate (Cc) and human menopausal gonadotropin (hMG) were used for ovulation
induction. After IUI, patients were randomized into two groups. The study group (n=98) received
intra-vaginal P (Cyclogest) for LPS. The patients randomized into the control group (n=102)
received no drug for LPS. The main outcome was the comparison of clinical pregnancy rate (PR)
and live birth rate (BR) per cycle and patient between the control and study groups.
Results: There were no differences in demographic characteristics between the groups. PR per
patient and cycle were similar in the study group (30.6% and 11.5%, respectively) and in the control
group [25.5% and 10.03%, respectively] (p&amp;amp;gt;0.05). There were no statistically significant increases
in BR per patient and cycle between the study group (19.4% and 7.5%, respectively) and the control
group [14.7% and 5.7%, respectively] (p&amp;amp;gt; 0.05).
Conclusion: Administration of vaginal P (Cyclogest) for LPS does not improve the reproductive
outcome of stimulated IUI cycles (Registeration Number: IRCT1389 01283737N1).</abstract>

	<keyword_fa></keyword_fa>
	<keyword>Clomiphene Citrate, Human Menopausal Gonadotropin, Progesterone, Infertility</keyword>
	<start_page>51</start_page>
	<end_page>56</end_page>
	<web_url></web_url>
	<web_url></web_url>
	<author_list>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Mahbod Ebrahimi, M.D</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email>maeb214@yahoo.com</email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Firoozeh Akbari Asbagh, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Soodabeh Darvish, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	</author_list>
</article>
  <article>
	<language></language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed></article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_isnet></article_id_isnet>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	
	<title_fa></title_fa>
	<title>Evaluation of Ovarian Reserve by Measurement of the Serum Levels of Anti-Mullerian Hormone and Follicle-Stimulating Hormone in Intracytoplasmic Sperm Injection Cycles</title>
	<subject_fa/>
	<subject/>
	
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	
	
	<abstract_fa></abstract_fa>
	<abstract>Background: It is important to evaluate ovarian reserves prior to intracytoplasmic sperm injection
(ICSI) treatment. The aim of this study is to determine the accuracy of anti-mullerian hormone
(AMH) as a marker for ovarian reserve and to compare it with day-3 serum follicle-stimulating
hormone (FSH) levels.
Materials and Methods: In this analytic, corss-sectional study, sequential sampling was done on
70 infertile women who underwent ICSI treatment at Imam Khomeini Hospital, Ahvaz, Iran.
Initially, 5cc of venous blood was drawn from each patient to measure serum AMH and FSH levels
on the day-3 cycle.
Patients were divided into two subgroups according to the numbers of oocytes retrieved. Patients
were classified as good responders if there were four or more oocytes retrieved, whereas patients
with less than four oocytes were poor responders.
Results: The basal AMH level correlated with the number of oocytes retrieved (linear Pearson
correlation coefficient=0.599), however the basal FSH level had a weakly reverse correlation
(correlation coefficient = -0.11).
AMH levels had a sensitivity of 85% and specificity of 61.5%, with a cutoff value equal to 2.3 ng/ml
which was higher than FSH.
Conclusion: AMH serum levels are good predictors of ovarian reserve in comparison with FSH.</abstract>

	<keyword_fa></keyword_fa>
	<keyword>AMH, FSH, ICSI</keyword>
	<start_page>57</start_page>
	<end_page>60</end_page>
	<web_url></web_url>
	<web_url></web_url>
	<author_list>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Roshan Nikbakht, M.D</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email>gita_yazdani@yahoo.com</email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Mehrdad Borhani, M.D</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Gita Yazdani Sarvestani, M.D</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	</author_list>
</article>
  <article>
	<language></language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed></article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_isnet></article_id_isnet>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	
	<title_fa></title_fa>
	<title>Photodynamic Therapy: A New Approach to Remove Embryos of the Wistar Rat</title>
	<subject_fa/>
	<subject/>
	
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	
	
	<abstract_fa></abstract_fa>
	<abstract>Background: Photodynamic therapy (PDT) is a promising new cancer treatment strategy which
inactivates tumor cells by simultaneoulsy using light and a photosensitizer. The similarity between
tumors and newly implanted embryos is notable. Extrauterine pregnancy (EUP) does not have a
definite treatment and previous therapeutic options (medical and surgical) have not been effective
or suitable. Therefore, PDT is suggested as a possible treatment for EUP.
Materials and Methods: The photosensitizer, hematoporphyrin, was injected locally into the
placenta of one selected embryo from a pregnant Wistar rat (E15). Then, a laser beam was
illuminated at the same point and 48 hours later, changes in the embryo and placenta were
investigated. Furthermore, the integrity of the uterus was examined by macroscopic evaluation
and sonographic images.
Results: Sections obtained from treated and control groups demonstrated that the embryo and
placenta were damaged in the PDT group, whereas the control ones were intact. Furthermore,
macroscopic observations and sonographic images during the second parturition after treatment
showed that the uterus was intact and fertility was preserved.
Conclusion: Successful ablation of the treated embryo with no clear damage to the uterus attests
to the success of this approach. The successful use of hematoporphyrin, as a first generation
photosensitizer, should be further investigated for its possible clinical applications.</abstract>

	<keyword_fa></keyword_fa>
	<keyword>Photodynamic Therapy (PDT), Ectopic Pregnancy, Embryo, Placenta, Fertility</keyword>
	<start_page>61</start_page>
	<end_page>66</end_page>
	<web_url></web_url>
	<web_url></web_url>
	<author_list>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Mohammad Nabiuni, Ph.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email>nabiuni@tmu.ac.ir</email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Mohammad Hossein Majles Ara, Ph.D</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Azar Sheikholeslami, M.Sc</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	</author_list>
</article>
  <article>
	<language></language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed></article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_isnet></article_id_isnet>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	
	<title_fa></title_fa>
	<title>Effects of Letrozole Compared with Danazol on Patients  with Confirmed Endometriosis: A Randomized Clinical Trial</title>
	<subject_fa/>
	<subject/>
	
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	
	
	<abstract_fa></abstract_fa>
	<abstract>Background: Letrozole is an aromatase inhibitor which can decrease estrogen production in
peripheral tissues and endometriosis. Danazol, as an androgen, inhibits estrogen production in
ovaries and recently has been introduced as an aromatase inhibitor. This study was designed to
compare the effects of Danazol with Letrozole on endometriosis symptom relief.
Materials and Methods: This study was a randomized clinical trial in which 105 patients with
confirmed endometriosis were randomly assigned to one of three groups. Group 1 received Letrozole
tablets (2.5 mg/day), calcium (1000 mg/day) and vitamin D (800 IU/day). Group 2 received Danazol
tablets (600 mg/day), calcium (1000 mg/day) and vitamin D (800 IU/day). Group 3 (placebo group)
were assigned to take two calcium tablets daily (500 mg/tablet) and vitamin D (800 IU/day). Pelvic
pain, dysmenorrhea and dyspareunia were assessed in participants at baseline and monthly during
the study for a total of six months. Data were analyzed via SPSS version 15 software with Freidman
and Wilcoxon tests.
Results: Mean age in three groups has no significant difference. Of the 105 participants who were
enrolled in this study, 38 patients were assigned to group 1 (Letrozole group), 37 patients in group 2
(Danazol group) and 31 patients were placed in group 3 (placebo group). This study showed that the
mean scores for chronic pelvic pain, dysmenorrhea and dyspareunia for the Letrozole group were
less than the Danazol and placebo groups.
Conclusion: This study showed that Letrozole can be more effective than Danazol for reducing
chronic pelvic pain, dyspareunia and dysmenorrhea in patients suffering from recurrent endometriosis
(Registeration Number: IRCT138812043414N1).</abstract>

	<keyword_fa></keyword_fa>
	<keyword>Letrozole, Danazol, Endometriosis, Laparoscopy</keyword>
	<start_page>62</start_page>
	<end_page>72</end_page>
	<web_url></web_url>
	<web_url></web_url>
	<author_list>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Mohamad Ali Roghaei, M.D</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email>taherian@med.mui.ac.ir</email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Hatav Ghasemi Tehrany, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Aliakbar Taherian, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Navid Koleini, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	</author_list>
</article>
  <article>
	<language></language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed></article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_isnet></article_id_isnet>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	
	<title_fa></title_fa>
	<title>Effects of Sperm DNA Fragmentation on Semen Parameters and ICSI Outcome Determined by an Improved SCD Test, Halosperm</title>
	<subject_fa/>
	<subject/>
	
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	
	
	<abstract_fa></abstract_fa>
	<abstract>Background: Sperm DNA fragmentation is known as an important cause of male infertility.
The influence of sperm DNA damage on reproductive potential has been subject of many studies
indicating various results and remaining the subject controversial. In this study, we investigated
differences of the semen parameters and intracytoplasmic sperm injection (ICSI) outcome according
to sperm DNA fragmentation levels (DFLs) of patients.
Materials and Methods: The DFLs were determined by Halosperm, a new improved sperm
chromatin dispersion (SCD) test. Patients were grouped as low DNA fragmentation group (LFG
≤30%) and high fragmentation group (HFG &amp;amp;gt;30%).
Results: Our analysis showed that semen parameters including concentration of untreated sperm
and motility of prepared semen were low in HGF, whereas other parameters were not different.
Sperm DNA fragmentation levels decreased in both groups after semen preparation by density
gradient technique.
Conclusion: No difference was detected on ICSI outcomes (fertilization, embryo development,
embryo cleavage, embryo quality and pregnancy rates) between two group.</abstract>

	<keyword_fa></keyword_fa>
	<keyword>Asisted Reproductive Technique, DNA Fragmentation, ICSI, Sperm</keyword>
	<start_page>73</start_page>
	<end_page>78</end_page>
	<web_url></web_url>
	<web_url></web_url>
	<author_list>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Seda Yılmaz, M.Sc.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email>seda2410@yahoo.com</email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Asuman Demiroglu Zergeroğlu, Ph.D</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Elif Yılmaz, B.Sc</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Kenan Sofuoglu, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Nuri Delikara, M.D</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Pelin Kutlu, M.Sc.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	</author_list>
</article>
  <article>
	<language></language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed></article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_isnet></article_id_isnet>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	
	<title_fa></title_fa>
	<title>Frequency of Hearing Defect and Ear Abnormalities in Newborns  Conceived by Assisted Reproductive Techniques in Royan Institute</title>
	<subject_fa/>
	<subject/>
	
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	
	
	<abstract_fa></abstract_fa>
	<abstract>Background: Assisted reproductive techniques (ART) are used with increasing frequency
worldwide. The present research was conducted to determine the effects of ART on hearing defects
and ear abnormalities.
Materials and Methods: In a descriptive, cross-sectional, non-randomized study, the status of
hearing and ear abnormalities was assessed in 300 newborns conceived by ART at Royan Institute,
Tehran, Iran. This study was performed over a sixteen month period.
Data were collected from parents, otoscopic examinations and transiently evoked otoacoustic
emissions (TEOAE) tests of the newborns. The external ear was assessed by otoscopic examination,
followed by the TEOAE test (an objective test that does not need the infant’s collaboration) which
was performed by an audiologist. In this test, the OAE wave was registered after a click (stimulus)
at 5-20 millisecond intervals with an 82 dB SPL altitude. Data were analyzed by statistical tests.
Results: Of the 300 cases examined by otoscopy, two cases (0.66%) had bilateral malformation
in the auricle, two (0.66%) had unilateral perforation of the tympanic membrane, five (1.66%)
had unilateral retraction of the tympanic membrane, eight (2.66%) had bilateral retraction of the
tympanic membrane, one (0.33%) had unilateral tympanic membrane inflammation, one (0.33%)
had bilateral tympanic membrane inflammation and one case (0.33%) had wax obstruction of the
external ear canal.
A total of 289 out of 300 newborns undewent the TEOAE test. Of these, three cases (1.03%) did not
have a bilateral registered wave and were diagnosed with bilateral hearing loss.
Conclusion: This study shows that hearing and ear screening in newborns conceived by ART
is contemplative and emphasizes the profitability of continual check up in these infants.</abstract>

	<keyword_fa></keyword_fa>
	<keyword>Newborn, Assisted Reproductive Techniques, Hearing, Ear</keyword>
	<start_page>79</start_page>
	<end_page>84</end_page>
	<web_url></web_url>
	<web_url></web_url>
	<author_list>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Seyed Ebrahim Ahmadi, M.Sc</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email>ahmadi@Irmed.org</email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Mohammad Reza Nateghi, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Hamid Gourabi, Ph.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Ramin Mozafari Kermani, M.D</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Farnoush Jarollahi, M.Sc.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Sodabeh Afsharpour, B.Sc</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Jalil Kouhpayehzadeh, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	</author_list>
</article>
  <article>
	<language></language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed></article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_isnet></article_id_isnet>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	
	<title_fa></title_fa>
	<title>Case Report : Coincidence of Cystic Fibrosis in Mother and her Child Related to Infertility</title>
	<subject_fa/>
	<subject/>
	
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	
	
	<abstract_fa></abstract_fa>
	<abstract>Cystic fibrosis (CF), the most common life-shortening, hereditary disease in whites, manifests
itself principally in childhood. Patients presenting with CF as adults appear to be different when
compared to patients diagnosed with CF during childhood. Often these patients have been previously
diagnosed with asthma, chronic bronchitis or emphysema.
We present a case of a woman diagnosed with CF at age 37 years. We noticed her finger clubbing
during her son’s hospital admission for CF decompensation. Taking a thorough history, she
complained of chronic productive cough and was treated for hyper reactive airway disease for many
years. A Computed Tomography scan was performed which showed bronchiectasis, atelectasis and
the presence of a honey comb pattern in her lung fields. Two sweat tests were performed, both of
which were strongly positive. Her CF diagnosis was confirmed.
The clinical course of patients receiving a diagnosis of CF in adulthood is largely unknown, but
frequently they have milder disease and a more favorable prognosis. The proportion and number of
patients with CF diagnosed in adulthood has increased. A large number of these patients present with
subtle symptoms or single-organ disease. Since the majority have pulmonary disease CF should be
included in the differential diagnosis of chronic respiratory symptoms in adults.</abstract>

	<keyword_fa></keyword_fa>
	<keyword>Cystic Fibrosis, Clubbing, Infertility, Pregnancy</keyword>
	<start_page>85</start_page>
	<end_page>87</end_page>
	<web_url></web_url>
	<web_url></web_url>
	<author_list>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Alireza Nikzad Jamnani, M.D</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email>alirezanikzad@yahoo.com</email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Mehri Najafi Sani, M.D</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Armen Malekiyan, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	</author_list>
</article>
  <article>
	<language></language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed></article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_isnet></article_id_isnet>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	
	<title_fa></title_fa>
	<title>Letter to the Editor : Diagnostic Accuracy of Transvaginal Sonography in Infertile Patients with Endometrial Polyps</title>
	<subject_fa/>
	<subject/>
	
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	
	
	<abstract_fa></abstract_fa>
	<abstract>To the Editor
We are interested the article by Niknejadi et al.
(1) highly scientific and provocative however
there seem to be a lack of clarity on some of the
methodological issues;
1. In the materials and methods section, it
was mentioned that: “in cases that had normal
endometrial findings on transvaginal sonography
(TVS), a hysteroscopy was not scheduled due to
ethical considerations” whereas in the results,
a total of 466 cases with negative TVS were
presented. It is not mentioned how these patients
were found. If they have other indications for
hysteroscopy, it may add bias to your research
which may affect the results (verification bias). The
bias would be present since both the TVS positive
and negative patients would come from different
patient populations that have different indications
as a result of their various medical conditions. For
example, most likely the TVS negative patients
in this study came from patients who presented
with in vitro fertilization (IVF) failure, intrauterine
insemination (IUI) failure and abnormalities seen
in clinical exams, to name a few. The TVS positive
cases would beare the people diagnosed during
routine TVS for infertility evaluation. Although
your research is retrospective, it would be better to
consider such differences between subjects (2-6).
2. Considering that TVS negative patients do not
routinely undergoto hysteroscopies; therefore
one can conclude that TVS is a highly sensitive
test, thus positive patients will not be missed.
Laparoscopy is a highly specific test needed solely
for confirming the diagnosed problem and can
88
Royan Institute
International Journal of Fertility and Sterility
Vol 4, No 2, Jul-Sep 2010
filter out healthy patients (2). It seems that in your
report, the sensitivity of TVS is not very high. On
the other hand, if we assume that there are some
degrees of verification bias in your study, the real
sensitivity even will be lower than calculated.</abstract>

	<keyword_fa></keyword_fa>
	<keyword>References
1. Niknejadi M, Ahmadi F, Zafarani F, Khalili M, Ghaderi
F, Rashidi Z. Diagnostic accuracy of transvaginal sonography
in infertile patients with endometrial polyps. International
Journal of Fertility and Sterillity (IJFS). 2010; 3
(4): 157-160.
2. Berek JS. Berek &amp;amp; Novak&amp;amp;#039;s Gynecology. 14th ed. Philadelphia:
Lippincott Williams &amp;amp; Wilkins; 2007; 787.
3. Ringham BM, Alonzo TA, Grunwald GK, Glueck H.
Estimates of sensitivity and specificity can be biased
when reporting the results of the second test in a screening
trial conducted in series. BMC Med Res Methodol.
2010; 10:3.
4. Buzoianu M, Kadane JB. Adjusting for verification
bias in diagnostic test evaluation: a Bayesian approach.
Stat Med. 2008; 27(13): 2453-2473.
5. Zhou XH.Correcting for verification bias in studies of
a diagnostic test&amp;amp;#039;s accuracy. Stat Methods Med Res.
1998; 7(4): 337-353
6. Cronin AM, Vickers AJ. Statistical methods to correct
for verification bias in diagnostic studies are inadequate
when there are few false negatives: a simulation study.
BMC Med Res Methodol. 2008; 8: 75.</keyword>
	<start_page>88</start_page>
	<end_page>88</end_page>
	<web_url></web_url>
	<web_url></web_url>
	<author_list>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Mona Oudi, B.Sc.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email>monaoudi@royaninstitute.org</email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Reza Omani Samani, M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email></email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	</author_list>
</article>
  <article>
	<language></language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed></article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_isnet></article_id_isnet>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	
	<title_fa></title_fa>
	<title>Reply of the Author : Diagnostic Accuracy of Transvaginal Sonography in Infertile Patients with Endometrial Polyps</title>
	<subject_fa/>
	<subject/>
	
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	
	
	<abstract_fa></abstract_fa>
	<abstract>Reply of the Authors
We welcome the opportunity to respond to the
letter of Dr. Samani and colleague:
1. A common problem of diagnostic research
in clinical medicine is that due to ethical or
cost considerations, only a small proportion of
participants with negative results may receive
the gold standard test. Therefore, the results for
diagnostic reference tests are more available in
patients with positive results. In this situation it is
very common to use the information that is available
from diagnostic tests in verified participants. Data
from such studies are prone to verification bias
(also called ‘work-up bias’).
As you are aware, we can not ethically prescribe
an invasive procedure, such as a hysteroscopy,
for humans without a reasonable indication.
Therefore we could not perform both diagnostic
tests (TVS and hysteroscopy) on all patients.
Instead, in our study, we attempted to find subjects
who had both results of TVS and hysteroscopy
in their medical records. We know that there is
an inevitable source of verification bias in our
results because of the subject selection strategy.
However, studies in this field often have a
similar selection strategy. There are some new
techniques for correcting verification bias and
currently we are analyzing our data to adjust for
verification bias (1-3).
2. The sensitiviy of our study is 88.3% which is
higher than similar studies in other countries (4,
5). This sensitivity is based on the hysteroscopic
89
Royan Institute
International Journal of Fertility and Sterility
Vol 4, No 2, Jul-Sep 2010
results as the gold standard, which is discussed
in our article. Hysteroscopy has some limitations;
therefore a prospective study should be planned
utilizing pathology as the gold standard.</abstract>

	<keyword_fa></keyword_fa>
	<keyword>References
1. Gaffikin L, McGrath J, Arbyn M, Blumenthal PD. Clin
Trials. Avoiding verification bias in screening test evaluation
in resource poor settings: a case study from Zimbabwe.
Clin Trials. 2008; 5(5): 496-503.
2. de Groot JA, Janssen KJ, Zwinderman AH, Moons
KG, Reitsma JB Multiple imputation to correct for partial
verification bias revisited. Stat Med. 2008; 27(28):
5880-5889.
3. Buzoianu M, Kadane JB. Adjusting for verification
bias in diagnostic test evaluation: a bayesian approach.
Stat Med. 2008; 27(13): 2453-2473.
4. Soares SR, Barbosa dos Reis MM, Camargos AF.
Diagnostic accuracy of sonohysterography, transvaginal
sonography, and hysterosalpingography in patients
with uterine cavity diseases. Fertil Steril. 2000; 73(2):
406-411.
5. Loverro G, Nappi L, Vicino M, Carriero C, Vimercati
A, Selvaggi L. Uterine cavity assessment in infertile
women: comparison of transvaginal sonography and
hysteroscopy. Eur J Obstet Gynecol Reprod Biol. 2001;
100(1): 67-71.</keyword>
	<start_page>89</start_page>
	<end_page>89</end_page>
	<web_url></web_url>
	<web_url></web_url>
	<author_list>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>Maryam Niknejadi M.D.</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email>mniknejadi@royaninstitute.org</email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	</author_list>
</article>
  <article>
	<language></language>
	<article_id_issn></article_id_issn>
	<article_id_issn_online></article_id_issn_online>
	<article_id_pubmed></article_id_pubmed>
	<article_id_pii></article_id_pii>
	<article_id_doi></article_id_doi>
	<article_id_isnet></article_id_isnet>
	<article_id_iranmedex></article_id_iranmedex>
	<article_id_magiran></article_id_magiran>
	<article_id_sid></article_id_sid>
	
	<title_fa></title_fa>
	<title>I-16: Computer Aided Sperm Analysis andSperm Functional Testing (Hyperactivation) asBackground Tools in the Evaluation of SpermFunction/Quality</title>
	<subject_fa/>
	<subject/>
	
	<content_type_fa></content_type_fa>
	<content_type></content_type>
	
	
	<abstract_fa></abstract_fa>
	<abstract>After twenty years Computer Aided Sperm Analysis has
developed considerably and is now routinely used in
many laboratories across the world. The advantage of
the CASA methodology available is twofold: Analysis of
particularly sperm concentration, sperm motility, sperm
morphology and vitality is quantified in an Background
manner. Secondly, most of the CASA analysis with the
exception of sperm morphology, is rapid and literally
takes a few seconds. These two factors allow scientists
to produce data in an Background and consistent manner
and also make experiments possible that would otherwise
have had too many time constraints. In this paper
emphasis will be placed on quantitative sperm motility
and its multiple uses in assessing sperm function in general
fertility studies; testing the effect of a vast range of
substances (peptides, hormones, toxicology) on sperm
function.
Two approaches will be described. In each instance either
sperm washing, swim-up or differential centrifugation
were used. When sperm were placed in media supporting
sperm function and largely simulate the composition
of follicular fluid after washing, a certain percentage of
sperm would become hyperactive. In good quality sperm
usually more than 20% of sperm become hyperactivewhen CASA parameters are set at VCL&amp;amp;gt;150; LIN7. Unfortunately sperm from different individuals
exhibit maximum hyperactivation at different time
intervals over three hours. However, in cases where a
specific strategy is required for a particular patient, additional
tests such as “the hyperactivation test” may be
useful. Also, the ability of a sperm sample to become
hyperactivated can be used to assess the effect of substances
such as pesticides and hormones on functional
integrity. A second useful CASA functional test that has
been developed in our laboratory, and used in certain
hormone assays is the percentage rapid moving sperm
in a sample and a cut-off point of VCL&amp;amp;gt;100 to 120 was
found most useful when washed samples were employed.
In conclusion, CASA now provides us with tools which
are reliable and consistent to study sperm function as
related to fertility and toxicology in a quantitative and
Background way.</abstract>

	<keyword_fa></keyword_fa>
	<keyword></keyword>
	<start_page>0</start_page>
	<end_page>0</end_page>
	<web_url></web_url>
	<web_url></web_url>
	<author_list>
	<author>
		<first_name></first_name>
		<middle_name/>
		<last_name></last_name>
		<suffix/>
		<affiliation></affiliation>
		<first_name_fa>van der Horst G</first_name_fa>
		<middle_name_fa></middle_name_fa>
		<last_name_fa></last_name_fa>
		<suffix_fa/>
		<email>raj.duggavathi@mcgill.ca</email>
		<code></code>
		<coreauthor>No</coreauthor>
		<affiliation_fa></affiliation_fa>
	</author>
	</author_list>
</article>
  
</articleset></journal>
  
